Literature DB >> 26620677

A flow cytometry-based reporter assay identifies macrolide antibiotics as nonsense mutation read-through agents.

Michal Caspi1, Anastasia Firsow1, Raja Rajkumar1, Nir Skalka1, Itay Moshkovitz1, Ariel Munitz1, Metsada Pasmanik-Chor2, Hagar Greif3, Dalia Megido3, Revital Kariv4, Daniel W Rosenberg5, Rina Rosin-Arbesfeld6.   

Abstract

UNLABELLED: A large number of human diseases are caused by nonsense mutations. These mutations result in premature protein termination and the expression of truncated, usually nonfunctional products. A promising therapeutic strategy for patients suffering from premature termination codon (PTC)-mediated disorders is to suppress the nonsense mutation and restore the expression of the affected protein. Such a suppression approach using specific antibiotics and other read-through promoting agents has been shown to suppress PTCs and restore the production of several important proteins. Here, we report the establishment of a novel, rapid, and very efficient method for screening stop-codon read-through agents. We also show that, in both mammalian cells and in a transgenic mouse model, distinct members of the macrolide antibiotic family can induce read-through of disease-causing stop codons leading to re-expression of several key proteins and to reduced disease phenotypes. Taken together, our results may help in the identification and characterization of well-needed customized pharmaceutical PTC suppression agents. KEY MESSAGES: Establishment of a flow cytometry-based reporter assay to identify nonsense mutation read-through agents. Macrolide antibiotics can induce read-through of disease-causing stop codons. Macrolide-induced protein restoration can alleviate disease-like phenotypes.

Entities:  

Keywords:  Aminoglycoside and macrolide antibiotics; Genetic diseases; Nonsense mutations; Premature termination codons (PTCs); Ribosomal read-through

Mesh:

Substances:

Year:  2015        PMID: 26620677     DOI: 10.1007/s00109-015-1364-1

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  59 in total

1.  Sequence analysis suggests that tetra-nucleotides signal the termination of protein synthesis in eukaryotes.

Authors:  C M Brown; P A Stockwell; C N Trotman; W P Tate
Journal:  Nucleic Acids Res       Date:  1990-11-11       Impact factor: 16.971

2.  Relationships among stop codon usage bias, its context, isochores, and gene expression level in various eukaryotes.

Authors:  Jingchun Sun; Ming Chen; Jinlin Xu; Jianhua Luo
Journal:  J Mol Evol       Date:  2005-09-13       Impact factor: 2.395

Review 3.  Translational termination efficiency in both bacteria and mammals is regulated by the base following the stop codon.

Authors:  W P Tate; E S Poole; J A Horsfield; S A Mannering; C M Brown; J G Moffat; M E Dalphin; K K McCaughan; L L Major; D N Wilson
Journal:  Biochem Cell Biol       Date:  1995 Nov-Dec       Impact factor: 3.626

4.  Aminoglycoside antibiotics mediate context-dependent suppression of termination codons in a mammalian translation system.

Authors:  M Manuvakhova; K Keeling; D M Bedwell
Journal:  RNA       Date:  2000-07       Impact factor: 4.942

5.  Repairing faulty genes by aminoglycosides: development of new derivatives of geneticin (G418) with enhanced suppression of diseases-causing nonsense mutations.

Authors:  Igor Nudelman; Dana Glikin; Boris Smolkin; Mariana Hainrichson; Valery Belakhov; Timor Baasov
Journal:  Bioorg Med Chem       Date:  2010-03-27       Impact factor: 3.641

6.  Effect of Readthrough Treatment in Fibroblasts of Patients Affected by Lysosomal Diseases Caused by Premature Termination Codons.

Authors:  Leslie Matalonga; Ángela Arias; Frederic Tort; Xènia Ferrer-Cortés; Judit Garcia-Villoria; Maria Josep Coll; Laura Gort; Antonia Ribes
Journal:  Neurotherapeutics       Date:  2015-10       Impact factor: 7.620

Review 7.  Pharmacologic therapy for stop mutations: how much CFTR activity is enough?

Authors:  Eitan Kerem
Journal:  Curr Opin Pulm Med       Date:  2004-11       Impact factor: 3.155

8.  Limited premature termination codon suppression by read-through agents in cystic fibrosis intestinal organoids.

Authors:  D D Zomer-van Ommen; L A W Vijftigschild; E Kruisselbrink; A M Vonk; J F Dekkers; H M Janssens; K M de Winter-de Groot; C K van der Ent; J M Beekman
Journal:  J Cyst Fibros       Date:  2015-08-05       Impact factor: 5.482

9.  Eukaryotic ribosomal RNA determinants of aminoglycoside resistance and their role in translational fidelity.

Authors:  Hua Fan-Minogue; David M Bedwell
Journal:  RNA       Date:  2007-11-14       Impact factor: 4.942

10.  Evaluation of Aminoglycoside and Non-Aminoglycoside Compounds for Stop-Codon Readthrough Therapy in Four Lysosomal Storage Diseases.

Authors:  Marta Gómez-Grau; Elena Garrido; Mónica Cozar; Víctor Rodriguez-Sureda; Carmen Domínguez; Concepción Arenas; Richard A Gatti; Bru Cormand; Daniel Grinberg; Lluïsa Vilageliu
Journal:  PLoS One       Date:  2015-08-19       Impact factor: 3.240

View more
  9 in total

1.  2-Aminothiazole-4-carboxamides Enhance Readthrough of Premature Termination Codons by Aminoglycosides.

Authors:  Safwat M Rabea; Alireza Baradaran-Heravi; Aruna D Balgi; Alexandra Krause; Sara Hosseini Farahabadi; Michel Roberge; David S Grierson
Journal:  ACS Med Chem Lett       Date:  2019-04-09       Impact factor: 4.345

Review 2.  Nonsense suppression therapies in human genetic diseases.

Authors:  Patrícia Martins-Dias; Luísa Romão
Journal:  Cell Mol Life Sci       Date:  2021-03-22       Impact factor: 9.261

3.  Serum starvation enhances nonsense mutation readthrough.

Authors:  Amnon Wittenstein; Michal Caspi; Yifat David; Yamit Shorer; Prathamesh T Nadar-Ponniah; Rina Rosin-Arbesfeld
Journal:  J Mol Med (Berl)       Date:  2019-11-15       Impact factor: 4.599

4.  Nonsense Suppression as an Approach to Treat Lysosomal Storage Diseases.

Authors:  Kim M Keeling
Journal:  Diseases       Date:  2016-10-19

Review 5.  Advances in therapeutic use of a drug-stimulated translational readthrough of premature termination codons.

Authors:  Maciej Dabrowski; Zuzanna Bukowy-Bieryllo; Ewa Zietkiewicz
Journal:  Mol Med       Date:  2018-05-29       Impact factor: 6.354

Review 6.  Selective toxicity of antibacterial agents-still a valid concept or do we miss chances and ignore risks?

Authors:  Axel Dalhoff
Journal:  Infection       Date:  2020-12-23       Impact factor: 7.455

7.  Properties of Non-Aminoglycoside Compounds Used to Stimulate Translational Readthrough of PTC Mutations in Primary Ciliary Dyskinesia.

Authors:  Maciej Dabrowski; Zuzanna Bukowy-Bieryllo; Claire L Jackson; Ewa Zietkiewicz
Journal:  Int J Mol Sci       Date:  2021-05-07       Impact factor: 5.923

Review 8.  Screening Readthrough Compounds to Suppress Nonsense Mutations: Possible Application to β-Thalassemia.

Authors:  Monica Borgatti; Emiliano Altamura; Francesca Salvatori; Elisabetta D'Aversa; Nicola Altamura
Journal:  J Clin Med       Date:  2020-01-21       Impact factor: 4.241

9.  Prediction of Premature Termination Codon Suppressing Compounds for Treatment of Duchenne Muscular Dystrophy Using Machine Learning.

Authors:  Kate Wang; Eden L Romm; Valentina L Kouznetsova; Igor F Tsigelny
Journal:  Molecules       Date:  2020-08-26       Impact factor: 4.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.